Sonya A Trinh1, Ignacio A Echenique2, Sudhir Penugonda1, Michael P Angarone1. 1. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2. Department of Infectious Diseases, Cleveland Clinic Florida, Weston, FL, USA.
Abstract
BACKGROUND: Diarrhea, a common complication after solid organ transplant (SOT), is associated with allograft failure and death. No evidence-based guidelines exist for the evaluation of diarrhea in SOT recipients. We performed a cost analysis to derive a testing algorithm for the diagnosis of community-onset diarrhea that minimizes costs without compromising diagnostic yields. DESIGN: A cost analysis was performed on a retrospective cohort of 422 SOT admissions for community-onset diarrhea over an 18-month period. A stepwise testing model was applied on a population level to assess test costs relative to diagnostic yields. RESULTS: Over an 18-month period, 1564 diagnostic tests were performed and 127 (8.1%) returned positive. Diagnostic testing accounted for $95 625 of hospital costs. The tests with the lowest cost per decrease in the false-omission rate (FOR) were stool Clostridium difficile polymerase chain reaction (PCR) ($156), serum cytomegalovirus quantitative PCR ($1529), stool norovirus (NV) PCR ($4673), and stool culture ($6804). A time-to-event analysis found no significant difference in the length of hospital stay between patients with and without NV testing (P=.520). CONCLUSIONS: A stepwise testing strategy can reduce costs without compromising diagnostic yields. In the first-stage testing, we recommend assessment for C. difficile, cytomegalovirus, and food-borne bacterial pathogens. For persistent diarrheal episodes, second-stage evaluation should include stool NV PCR, Giardia/Cryptosporidium enzyme immunoassay, stool ova and parasite, reductions in immunosuppressive therapy, and possibly endoscopy. Although NV testing had a relatively low cost per FOR, we recommend NV testing during second-stage evaluation, as an NV diagnosis may not lead to changes in clinical management or further reductions in length of hospital stay.
BACKGROUND:Diarrhea, a common complication after solid organ transplant (SOT), is associated with allograft failure and death. No evidence-based guidelines exist for the evaluation of diarrhea in SOT recipients. We performed a cost analysis to derive a testing algorithm for the diagnosis of community-onset diarrhea that minimizes costs without compromising diagnostic yields. DESIGN: A cost analysis was performed on a retrospective cohort of 422 SOT admissions for community-onset diarrhea over an 18-month period. A stepwise testing model was applied on a population level to assess test costs relative to diagnostic yields. RESULTS: Over an 18-month period, 1564 diagnostic tests were performed and 127 (8.1%) returned positive. Diagnostic testing accounted for $95 625 of hospital costs. The tests with the lowest cost per decrease in the false-omission rate (FOR) were stool Clostridium difficile polymerase chain reaction (PCR) ($156), serum cytomegalovirus quantitative PCR ($1529), stool norovirus (NV) PCR ($4673), and stool culture ($6804). A time-to-event analysis found no significant difference in the length of hospital stay between patients with and without NV testing (P=.520). CONCLUSIONS: A stepwise testing strategy can reduce costs without compromising diagnostic yields. In the first-stage testing, we recommend assessment for C. difficile, cytomegalovirus, and food-borne bacterial pathogens. For persistent diarrheal episodes, second-stage evaluation should include stool NV PCR, Giardia/Cryptosporidium enzyme immunoassay, stool ova and parasite, reductions in immunosuppressive therapy, and possibly endoscopy. Although NV testing had a relatively low cost per FOR, we recommend NV testing during second-stage evaluation, as an NV diagnosis may not lead to changes in clinical management or further reductions in length of hospital stay.
Authors: B Maes; K Hadaya; B de Moor; P Cambier; P Peeters; J de Meester; J Donck; J Sennesael; J-P Squifflet Journal: Am J Transplant Date: 2006-06 Impact factor: 8.086
Authors: Christine M Durand; Kieren A Marr; Christina A Arnold; Lydia Tang; Daniel J Durand; Robin K Avery; Alexandra Valsamakis; Dionissios Neofytos Journal: Clin Infect Dis Date: 2013-08-15 Impact factor: 9.079
Authors: John P Rice; Bret J Spier; Daniel D Cornett; Andrew J Walker; Kelly Richie; Patrick R Pfau Journal: Transplantation Date: 2009-08-15 Impact factor: 4.939
Authors: Simon D Goldenberg; Mariana Bacelar; Peter Brazier; Karen Bisnauthsing; Jonathan D Edgeworth Journal: J Infect Date: 2014-11-29 Impact factor: 6.072
Authors: Ignacio A Echenique; Sudhir Penugonda; Valentina Stosor; Michael G Ison; Michael P Angarone Journal: Clin Infect Dis Date: 2014-11-03 Impact factor: 9.079
Authors: H Weclawiak; A Ould-Mohamed; B Bournet; C Guilbeau-Frugier; F Fortenfant; F Muscari; F Sallusto; C Dambrin; L Esposito; J Guitard; M Abbal; L Rostaing; N Kamar Journal: Am J Transplant Date: 2011-02-07 Impact factor: 8.086
Authors: Christopher R Polage; Clare E Gyorke; Michael A Kennedy; Jhansi L Leslie; David L Chin; Susan Wang; Hien H Nguyen; Bin Huang; Yi-Wei Tang; Lenora W Lee; Kyoungmi Kim; Sandra Taylor; Patrick S Romano; Edward A Panacek; Parker B Goodell; Jay V Solnick; Stuart H Cohen Journal: JAMA Intern Med Date: 2015-11 Impact factor: 21.873